CON-TGO91-311 - Novartis Pharmaceuticals Australia Pty Ltd
Product names
- AUST R 71445 - EXELON rivastigmine 1.5mg (as hydrogen tartrate) capsule blister pack
- AUST R 71446 - EXELON rivastigmine 3.0mg (as hydrogen tartrate) capsule blister pack
- AUST R 71447 - EXELON rivastigmine 4.5mg (as hydrogen tartrate) capsule blister pack
- AUST R 71448 - EXELON rivastigmine 6mg (as hydrogen tartrate) capsule blister pack
- AUST R 133422 - EXELON PATCH 5 rivastigmine 4.6mg/24 hours transdermal drug delivery system sachet
- AUST R 133428 - EXELON PATCH 10 rivastigmine 9.5mg/24 hours transdermal drug delivery system sachet
- AUST R 222604 - EXELON PATCH 15 rivastigmine 13.3mg/24 hours transdermal drug delivery system sachet
Decision Date
Duration
The consent is effective for all batches manufactured between 1 September 2020 and 30 April 2021.
Non-compliance with standard
The product(s) do not conform with the requirements of TGO 91 but are supplied with label(s) that have been approved by the TGA.
Supply/Import or Export
Supply
Therapeutic good type
Prescription medicines